6 results on '"ALHAN, Fadime Nurcan"'
Search Results
2. Clinical and Survival Outcomes in Patients with Supra-Diaphragmatic Vs İnfra-Diaphragmatic Diffuse Large B Cell Lymphoma
- Author
-
ILTAR, Utku, ÜNDAR, Levent, SALİM, Ozan, YÜCEL, Orhan Kemal, ALHAN, Fadime Nurcan, VURAL, Ece, ATAŞ, Ünal, and DEVECİ, Burak
- Subjects
Health Care Sciences and Services ,Infradiaphragmatic ,supradiaphragmatic ,diffuse large B-cell lymphoma ,prognosis ,Sağlık Bilimleri ve Hizmetleri ,İnfradiyafragmatik ,supradiyafragmatik ,diffüz büyük B hücreli lenfoma ,prognoz - Abstract
Erken evre diffüz büyük B hücreli lenfoma (DBBHL), tüm DBBHL olgularının yaklaşık %30'unu oluşturur. Bu çalışma, birinci basamak rituksimab, siklofosfamid, doksorubisin, vinkristin ve prednizon (R-CHOP) ile tedavi edilen erken evre DBBHL tanılı hastalarda diyaframa göre lenfoma tutulum tarafının klinik ve sağkalım sonuçları üzerine etkisini araştırmayı amaçladı. 2010 ve 2019 yılları arasında R-CHOP alan erken evreli 93 DBBHL tanılı hastadan veriler geriye dönük olarak analiz edildi. Hastalar diyafram tarafına göre iki alt gruba ayrıldı: 29 infradiyafragmatik (InD) ve 64 supradiyafragmatik (SpD) hasta. Sağkalım sonuçlarında anlamlı bir fark yoktu [SpD ve InD gruplarının 5 yıllık PFS oranı, sırasıyla %76.7 ve %85.7 (P =0.553); SpD ve InD gruplarının 5 yıllık OS oranları, sırasıyla %82.1 ve %89,1 (P = 0,524)]. Ayrıca, klinik özellikler açısından InD grupta ekstra nodal tutulumun baskın olması ve SpD grupta daha yüksek IPI mevcut olması dışında anlamlı farklılık yoktu. Sonuç olarak, erken evre DBBHL'de, tutulum alanı diyaframın altındaysa ekstra nodal tutulum daha fazla beklenir, ancak tutulum alanının diyaframın altında veya üstünde olmasının sağkalım sonuçları üzerine etkisi yoktur. Bu sonuçlarının daha geniş bir hasta grubuyla yapılacak yeni çalışmalarla doğrulanması gerekmektedir., Limited-stage diffuse large B-cell lymphoma (DLBCL) accounts for approximately 30% of all DLBCL cases. This study aimed to investigate the impact of the lymphoma involvement side relative to the diaphragm on clinical and survival outcomes in patients with limited-stage DLBCL treated with first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Data from 93 patients with limited-stage DLBCL between 2010 and 2019 receiving R-CHOP were retrospectively analyzed. Patients were divided into two subgroups according to the side of the diaphragm: 29 patients with infradiaphragmatic (InD) and 64 patients with supradiaphragmatic (SpD). There were no significant differences in survival outcomes [5-year PFS rate of SpD and InD groups, 76.7% and 85.7%, respectively (P =0.553); 5-year OS rates of SpD and InD groups, 82.1% and 89.1%, respectively (P = 0,524)] and clinical characteristics, except that extra nodal involvement was dominant in the InD group and the SpD group had a higher IPI. In conclusion, in early-stage DLBCL, extra nodal involvement is expected more if the primary involvement area is below the diaphragm, however whether the primary involvement area is below or above the diaphragm has no effect on survival outcomes. The results of this study need to be confirmed by further studies with a larger case group.
- Published
- 2022
3. Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome
- Author
-
Iltar, Utku, primary, Alhan, Fadime Nurcan, additional, Vural, Ece, additional, Ataş, Ünal, additional, Sözel, Hasan, additional, Doğan, Ömer, additional, Boduroğlu, Ahmet, additional, Yücel, Orhan Kemal, additional, Salim, Ozan, additional, and Ündar, Levent, additional
- Published
- 2021
- Full Text
- View/download PDF
4. Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome.
- Author
-
Iltar, Utku, Alhan, Fadime Nurcan, Vural, Ece, Ataş, Ünal, Sözel, Hasan, Doğan, Ömer, Boduroğlu, Ahmet, Yücel, Orhan Kemal, Salim, Ozan, and Ündar, Levent
- Subjects
- *
DISEASE relapse , *DRUG therapy for arthritis , *MYELODYSPLASTIC syndromes , *NONSTEROIDAL anti-inflammatory agents , *AZACITIDINE , *TREATMENT effectiveness , *PANCYTOPENIA , *BLOOD platelet transfusion , *ARTHRITIS , *RED blood cell transfusion , *DISEASE exacerbation - Abstract
Introduction: Hypomethylating agents have confirmed efficacy for myelodysplastic syndrome and acute myeloid leukemia and are widely used. Although arthralgia is common side effect associated with hypomethylating agents, arthritis has not been reported previously. Case Report: We present the first recorded patient with arthritis after azacitidine treatment. The patient we presented here had severe cytopenias requiring transfusion with erythrocyte and platelet suspensions, and a complete hematological response was obtained for myelodysplastic syndrome after three cycles of azacitidine (AZA) treatment. However, interestingly, after each AZA treatment cycle, the patient had recurrent attacks of arthritis. Management and outcomes: The episodes of arthritis were possibly acute flares of pre-existing crystal-induced arthritis, as exhibited with azacitidine treatments and were managed effectively with nonsteroidal anti-inflammatory drugs. Discussion: Because it is a rare condition, clinicians should not overlook AZA as a possible cause of arthritis exacerbations when arthritis of unknown etiology develops in patients treated with AZA. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Real-Life Experience of Dose-Adjusted Venetoclax in Acute Myeloid Leukemia Patients Concomitantly Using Posaconazole for Antifungal Prophylaxis: A Single-Center Experience.
- Author
-
ILTAR, Utku, VURAL, Ece, ALHAN, Fadime Nurcan, VURGUN, Sertac, ATAS, Unal, YUCEL, Orhan Kemal, Salim, Ozan, ULAS, Turgay, COSKUN, Mert, TOYLU, Asli, KARAUZUM, Sibel Berker, and UNDAR, Levent
- Subjects
- *
ACUTE myeloid leukemia , *CYTOCHROME P-450 CYP3A , *VENETOCLAX , *ECHINOCANDINS , *PREVENTIVE medicine , *MYCOSES - Abstract
The treatment process in acute myeloid leukemia (AML) often results in prolonged neutropenia, especially in the early period, and this requires antifungal prophylaxis. In the era of venetoclax (VEN), concomitant antifungal prophylaxis has been abandoned because azole antifungals inhibit cytochrome P450 3A4, the primary enzyme responsible for VEN metabolism. If azole antifungal prophylaxis is used with VEN, the dose of VEN needs to be reduced, but the clinical consequences in this situation are unknown. Limited clinical data exist on outcomes for patients treated with VEN, a hypomethylating agent (HMA), and posaconazole. We retrospectively evaluated our single-center experience on 46 patients, 20 treatment-naive and 26 relapsed/refractory (RR) AML patients. VEN was used after dose adjustment due to concomitant posaconazole use for antifungal prophylaxis. The median age was 65.5 years (range, 18-78). The median follow-up was 5.5 months (range, 1-25). The overall response rate (ORR) was 60.8%. The incidence of invasive fungal infection was 15.2%. The median OS from venetoclax initiation of all the patients and those with CR/CRi was 6 and 10 months, respectively. After VEN dose reduction due to concomitant posaconazole use, the observed ORR was comparable to the ORR previously reported in the literature without VEN dose reduction and antifungal prophylaxis. However, the OS obtained in our patients was shorter than previously reported in the literature. In addition, the incidence of invasive fungal infections in our patients was not less than that reported in the VEN and HMA studies without antifungal prophylaxis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib-Based Therapy: A Real-Life Multicenter Experienc on Off-Label Use of Ibrutinib.
- Author
-
ILTAR, Utku, SALIM, Ozan, ATAS, Unal, VURAL, Ece, ALHAN, Fadime Nurcan, YUCEL, Orhan Kemal, SOZEL, Hasan, GUVEN, Serkan, GEDUK, Ayfer, DEVECI, Burak, SERIN, Istemi, ELVERDI, Tugrul, KARADAG, Fatma Keklik, KARAKUS, Volkan, MALKAN, Umit Yavuz, TOMBAK, Anil, ULAS, Turgay, TARKUN, Pinar, ESKAZAN, Ahmet Emre, and ALACACIOGLU, Inci
- Subjects
- *
OFF-label use (Drugs) , *TREATMENT effectiveness , *PULMONARY aspergillosis , *CENTRAL nervous system , *MYCOSES , *LYMPHOMAS - Abstract
Despite recent therapeutic advances, the prognosis of patients with relapsed/refractory (RR) primary (PCNSL) and secondary central nervous system lymphoma (SCNSL) remains poor. Therefore, the need for new treatment options in CNSL continues. Ibrutinib has been used in clinical trials for CNSL in recent years. However, there is no real-life data on this subject yet. We retrospectively evaluated the efficacy of ibrutinib alone or in combination with various treatment options in 39 patients, 21 with PCNSL and 18 with SCNSL. The median age was 62 years and the overall response rate (ORR) was 59%. The median overall survival (OS) was four months for all patients and 13 months for responder patients (p< 0.001). Invasive aspergillosis occurred in 10.2% of the patients. Lactate dehy-drogenase activity, response to treatment, and the presence of the invasive fungal infection were prognostic factors affecting OS on the ibrutinib therapy (p= 0.04, p= 0.02, and p= 0.048, respectively). There was no significant difference in prognosis between the IBR monotherapy and IBR combination groups. Compared to early-phase clinical studies, lower ORR, shorter OS, and a higher incidence of invasive fungal infections were observed in this real-life study of ibrutinib which was used alone or in a combination regimen in patients with RR PCNSL and SCNSL. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.